DoD's $693M contract for COVID-19 pharmaceutical manufacturing capacity to yield 100M doses annually

Contract Overview

Contract Amount: $69,300,000 ($69.3M)

Contractor: Continuus Pharmaceuticals, Inc.

Awarding Agency: Department of Defense

Start Date: 2021-01-15

End Date: 2023-05-12

Contract Duration: 847 days

Daily Burn Rate: $81.8K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: COVID-19 DHHS CAPACITY EXPANSION TO PROVIDE INTEGRATED CONTINUOUS MANUFACTURING OF THREE COVID RELATED PHARMACEUTICALS. CONTRACT WILL RESULT IN CAPACITY TO PRODUCE 100M DOSES PER YEAR.

Place of Performance

Location: WOBURN, MIDDLESEX County, MASSACHUSETTS, 01801

State: Massachusetts Government Spending

Plain-Language Summary

Department of Defense obligated $69.3 million to CONTINUUS PHARMACEUTICALS, INC. for work described as: COVID-19 DHHS CAPACITY EXPANSION TO PROVIDE INTEGRATED CONTINUOUS MANUFACTURING OF THREE COVID RELATED PHARMACEUTICALS. CONTRACT WILL RESULT IN CAPACITY TO PRODUCE 100M DOSES PER YEAR. Key points: 1. Contract aims to bolster domestic pharmaceutical manufacturing capabilities for critical health threats. 2. Significant investment in advanced manufacturing technology for rapid response. 3. Focus on continuous manufacturing processes for efficiency and scalability. 4. Potential to reduce reliance on foreign supply chains for essential medicines. 5. Long-term contract duration suggests sustained need for these capabilities. 6. Fixed-price contract structure provides cost certainty for the government.

Value Assessment

Rating: good

The contract's value of $693 million for establishing manufacturing capacity appears reasonable given the strategic importance of domestic pharmaceutical production for COVID-19 related drugs. While direct comparisons are difficult due to the unique nature of pandemic preparedness investments, the cost is aligned with large-scale industrial build-outs. The firm fixed-price structure helps manage cost overruns, indicating a potentially good value for taxpayer dollars in securing future production capabilities.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, suggesting that multiple capable vendors had the opportunity to bid. The specific number of bidders is not provided, but the open competition process generally promotes competitive pricing and encourages innovation. This approach is favorable for ensuring the government receives the best possible value and technological solutions.

Taxpayer Impact: Full and open competition is beneficial for taxpayers as it drives down prices through market forces and increases the likelihood of selecting the most cost-effective and capable solution.

Public Impact

The primary beneficiaries are the American public, through increased access to domestically produced COVID-19 related pharmaceuticals. The contract delivers enhanced manufacturing capacity, crucial for responding to future public health emergencies. Geographic impact is centered in Massachusetts, fostering local economic development and job creation in the pharmaceutical sector. Workforce implications include the creation of skilled jobs in advanced manufacturing, quality control, and pharmaceutical production.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Long-term commitment could lead to vendor lock-in if not managed carefully.
Reliance on a single contractor for critical manufacturing capacity carries inherent supply chain risks.
Ensuring sustained demand and utilization post-pandemic is crucial for long-term value.
Potential for cost increases if unforeseen technological challenges arise during setup.

Positive Signals

Establishes critical domestic manufacturing infrastructure, enhancing national security.
Promotes technological advancement in pharmaceutical production processes.
Supports economic growth and job creation within the United States.
Builds resilience against global supply chain disruptions for essential medicines.

Sector Analysis

This contract falls within the Pharmaceutical Preparation Manufacturing sector, a critical component of the broader healthcare and life sciences industry. The market for pharmaceutical manufacturing is substantial, driven by ongoing demand for medicines and increasing focus on supply chain security. This contract represents a significant government investment aimed at building domestic capacity, potentially influencing market dynamics by creating a large-scale, government-supported production facility.

Small Business Impact

The data indicates this contract was not set aside for small businesses, nor does it explicitly mention subcontracting goals for small businesses. The scale of this project likely favors large, established manufacturing firms. Further analysis would be needed to determine if opportunities exist for small businesses within the supply chain or through specialized support services.

Oversight & Accountability

Oversight for this contract will likely be managed by the Department of Defense, potentially through its contracting command and relevant program offices. Accountability measures are inherent in the firm fixed-price structure, which incentivizes the contractor to meet defined deliverables within budget. Transparency will depend on the agency's reporting practices and public availability of contract performance data.

Related Government Programs

COVID-19 Vaccine Manufacturing Initiatives
Biopharmaceutical Production Contracts
National Biodefense Strategy Investments
Advanced Manufacturing Technology Programs

Risk Flags

Potential for supply chain disruption if contractor faces operational issues.
Long-term reliance on a single facility for critical capacity.
Ensuring sustained demand and utilization post-pandemic.
Technological obsolescence risk in a rapidly evolving field.

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $69.3 million to CONTINUUS PHARMACEUTICALS, INC.. COVID-19 DHHS CAPACITY EXPANSION TO PROVIDE INTEGRATED CONTINUOUS MANUFACTURING OF THREE COVID RELATED PHARMACEUTICALS. CONTRACT WILL RESULT IN CAPACITY TO PRODUCE 100M DOSES PER YEAR.

Who is the contractor on this award?

The obligated recipient is CONTINUUS PHARMACEUTICALS, INC..

Which agency awarded this contract?

Awarding agency: Department of Defense (Department of the Air Force).

What is the total obligated amount?

The obligated amount is $69.3 million.

What is the period of performance?

Start: 2021-01-15. End: 2023-05-12.

What is the track record of Continuus Pharmaceuticals, Inc. in fulfilling large-scale government manufacturing contracts, particularly in the pharmaceutical sector?

Information regarding Continuus Pharmaceuticals, Inc.'s specific track record with large-scale government manufacturing contracts, especially within the pharmaceutical sector, is not detailed in the provided data. A comprehensive assessment would require reviewing past performance evaluations, contract history, and any reported issues or successes with previous government engagements. Understanding their experience with similar production volumes, regulatory compliance (e.g., FDA standards), and project management for complex manufacturing facilities is crucial for evaluating their capability to execute this significant contract effectively.

How does the per-unit cost of production compare to similar domestic or international pharmaceutical manufacturing facilities, considering the scale and technology employed?

The provided data does not include specific per-unit cost of production figures or benchmarks for comparison. Establishing such a benchmark would involve analyzing the operational costs, including raw materials, labor, energy, and overhead, against similar facilities. Given the contract's focus on establishing new capacity using continuous manufacturing, initial per-unit costs might be higher during the ramp-up phase compared to established, scaled operations. However, the long-term goal of continuous manufacturing is often to achieve lower operational costs and higher efficiency once fully operational, potentially making it competitive over the contract's lifespan.

What are the key performance indicators (KPIs) and milestones defined in the contract to measure the successful establishment and operation of the manufacturing capacity?

The provided data does not specify the key performance indicators (KPIs) or milestones for this contract. Typically, such a contract would include detailed metrics related to the construction and commissioning of the facility, achievement of production targets (e.g., meeting the 100 million doses per year capacity), quality control standards (e.g., adherence to Good Manufacturing Practices - GMP), and potentially timelines for specific drug production capabilities. The agency would monitor these KPIs to ensure the contractor is meeting its obligations and delivering the intended value.

What is the projected timeline for the full operational capacity of 100 million doses per year, and what are the potential risks associated with delays?

The contract duration is 847 days (approximately 2.3 years) from the award date of January 15, 2021, to the estimated completion date of May 12, 2023. This duration suggests the timeline for achieving full operational capacity is within this period. Potential risks associated with delays include increased costs, failure to meet national security or public health needs for pharmaceutical supply, and potential penalties or contract modifications. The agency would likely have provisions for managing and mitigating such delays.

How does this investment align with broader U.S. government strategies for pharmaceutical supply chain resilience and pandemic preparedness?

This contract directly aligns with broader U.S. government strategies aimed at enhancing pharmaceutical supply chain resilience and bolstering pandemic preparedness. Initiatives like the National Biodefense Strategy and efforts to onshore critical manufacturing capabilities are designed to reduce reliance on foreign sources and ensure timely access to essential medicines during crises. By investing in domestic manufacturing capacity for COVID-19 related pharmaceuticals, the Department of Defense is actively contributing to these strategic goals, ensuring the nation has the means to respond effectively to health emergencies.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: FA850521R0006

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 25-R OLYMPIA AVE, WOBURN, MA, 01801

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $69,300,000

Exercised Options: $69,300,000

Current Obligation: $69,300,000

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Timeline